Maravai LifeSciences (MRVI): Price and Financial Metrics
GET POWR RATINGS... FREE!
MRVI POWR Grades
- Quality is the dimension where MRVI ranks best; there it ranks ahead of 87.08% of US stocks.
- MRVI's strongest trending metric is Growth; it's been moving up over the last 179 days.
- MRVI's current lowest rank is in the Stability metric (where it is better than 12.35% of US stocks).
MRVI Stock Summary
- Maravai Lifesciences Holdings Inc's stock had its IPO on November 20, 2020, making it an older stock than merely 1.84% of US equities in our set.
- With a price/sales ratio of 11.58, Maravai Lifesciences Holdings Inc has a higher such ratio than 87.33% of stocks in our set.
- As for revenue growth, note that MRVI's revenue has grown 181.32% over the past 12 months; that beats the revenue growth of 95.46% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Maravai Lifesciences Holdings Inc, a group of peers worth examining would be HCDI, LIVE, ACTG, RMR, and GNOG.
- MRVI's SEC filings can be seen here. And to visit Maravai Lifesciences Holdings Inc's official web site, go to www.maravai.com.
MRVI Valuation Summary
- In comparison to the median Healthcare stock, MRVI's price/sales ratio is 373.13% higher, now standing at 53.7.
- MRVI's price/sales ratio has moved down 0.1 over the prior 41 weeks.
- MRVI's EV/EBIT ratio has moved down 195.2 over the prior 41 weeks.
Below are key valuation metrics over time for MRVI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MRVI | 2021-08-31 | 53.7 | 78.6 | 171.4 | 126.1 |
| MRVI | 2021-08-30 | 54.2 | 79.4 | 173.0 | 127.3 |
| MRVI | 2021-08-27 | 54.0 | 79.1 | 172.5 | 126.9 |
| MRVI | 2021-08-26 | 53.7 | 78.6 | 171.4 | 126.1 |
| MRVI | 2021-08-25 | 54.3 | 79.6 | 173.5 | 127.7 |
| MRVI | 2021-08-24 | 54.7 | 80.2 | 174.8 | 128.6 |
MRVI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MRVI has a Quality Grade of C, ranking ahead of 71.9% of graded US stocks.
- MRVI's asset turnover comes in at 0.307 -- ranking 150th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows MRVI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.307 | 0.72 | 0.155 |
MRVI Price Target
For more insight on analysts targets of MRVI, see our MRVI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $49.33 | Average Broker Recommendation | 1.22 (Strong Buy) |
MRVI Stock Price Chart Interactive Chart >
MRVI Price/Volume Stats
| Current price | $34.28 | 52-week high | $63.55 |
| Prev. close | $34.50 | 52-week low | $23.16 |
| Day low | $33.94 | Volume | 955,000 |
| Day high | $35.22 | Avg. volume | 2,038,975 |
| 50-day MA | $34.04 | Dividend yield | N/A |
| 200-day MA | $39.13 | Market Cap | 8.75B |
Maravai LifeSciences (MRVI) Company Bio
Maravai Lifesciences Holdings, Inc. operates as an investment holding company. It develops biopharmaceuticals. The company is headquartered in San Diego, CA.
Latest MRVI News From Around the Web
Below are the latest news stories about Maravai Lifesciences Holdings Inc that investors may wish to consider to help them evaluate MRVI as an investment opportunity.
Maravai Life Sciences jumps on report of $11B bid from SartoriusMaravai Life Sciences (NASDAQ:MRVI) soared 17% after a report that Sartorius AG offered to buy the the company for $11B. Maravai rejected the $42/share offer from Goettingen, Germany-based Sartorius, according to a Reuters report. Not clear if Sartorius may return with another offer or MRVI may see interest from other companies.... |
Can Maravai LifeSciences Holdings, Inc. (MRVI) Run Higher on Rising Earnings Estimates?Maravai LifeSciences Holdings, Inc. (MRVI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
Maravai LifeSciences Holdings, Inc. 2021 Q4 - Results - Earnings Call PresentationThe following slide deck was published by Maravai LifeSciences Holdings, Inc. in conjunction with their 2021 Q4 earnings call.... |
Can Maravai LifeSciences Holdings, Inc. (MRVI) Climb 56% to Reach the Level Wall Street Analysts Expect?The consensus price target hints at a 55.8% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 Earnings and Revenues Beat EstimatesMaravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 18.42% and 10.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
MRVI Price Returns
| 1-mo | 12.17% |
| 3-mo | -7.63% |
| 6-mo | -20.65% |
| 1-year | -8.68% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -18.19% |
| 2021 | 49.38% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...